141 related articles for article (PubMed ID: 23092099)
1. Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2.
Mizutani N; Ito H; Hagiwara K; Kobayashi M; Hoshikawa A; Nishida Y; Takagi A; Kojima T; Suzuki M; Osawa Y; Ohnishi K; Daibata M; Murate T
Nagoya J Med Sci; 2012 Aug; 74(3-4):261-71. PubMed ID: 23092099
[TBL] [Abstract][Full Text] [Related]
2. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
3. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
5. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
6. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
7. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
8. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Gamba S; Camaj P; Heinemann V; Laubender RP; Wang Y; Zhao Y; Stintzing S; Giessen C; Boeck S; Haertl C; Bruns CJ; Modest DP
Anticancer Drugs; 2015 Apr; 26(4):371-8. PubMed ID: 25514114
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia.
Teramo A; Gattazzo C; Passeri F; Lico A; Tasca G; Cabrelle A; Martini V; Frezzato F; Trimarco V; Ave E; Boscaro E; Piazza F; Facco M; Trentin L; Semenzato G; Zambello R
Blood; 2013 May; 121(19):3843-54, S1. PubMed ID: 23515927
[TBL] [Abstract][Full Text] [Related]
10. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
13. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
14. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
15. Submicroscopic genomic rearrangements change gene expression in T-cell large granular lymphocyte leukemia.
Iżykowska K; Zawada M; Nowicka K; Grabarczyk P; Kuss AW; Weissmann R; Busemann C; Ludwig WD; Schmidt CA; Przybylski GK
Eur J Haematol; 2014 Aug; 93(2):143-9. PubMed ID: 24649974
[TBL] [Abstract][Full Text] [Related]
16. Characterization of KRAS rearrangements in metastatic prostate cancer.
Wang XS; Shankar S; Dhanasekaran SM; Ateeq B; Sasaki AT; Jing X; Robinson D; Cao Q; Prensner JR; Yocum AK; Wang R; Fries DF; Han B; Asangani IA; Cao X; Li Y; Omenn GS; Pflueger D; Gopalan A; Reuter VE; Kahoud ER; Cantley LC; Rubin MA; Palanisamy N; Varambally S; Chinnaiyan AM
Cancer Discov; 2011 Jun; 1(1):35-43. PubMed ID: 22140652
[TBL] [Abstract][Full Text] [Related]
17. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
Kiessling MK; Oberholzer PA; Mondal C; Karpova MB; Zipser MC; Lin WM; Girardi M; Macconaill LE; Kehoe SM; Hatton C; French LE; Garraway LA; Polier G; Süss D; Klemke CD; Krammer PH; Gülow K; Dummer R
Blood; 2011 Feb; 117(8):2433-40. PubMed ID: 21209378
[TBL] [Abstract][Full Text] [Related]
18. IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells.
Fung MM; Rohwer F; McGuire KL
Cell Signal; 2003 Jun; 15(6):625-36. PubMed ID: 12681450
[TBL] [Abstract][Full Text] [Related]
19. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
20. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy.
Kato M; Yasui N; Seki M; Kishimoto H; Sato-Otsubo A; Hasegawa D; Kiyokawa N; Hanada R; Ogawa S; Manabe A; Takita J; Koh K
J Pediatr; 2013 Jun; 162(6):1285-8, 1288.e1. PubMed ID: 23403250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
